Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62.9M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
-3.46M
-
Total reported value, excl. options
-
$49.2M
-
Value change
-
-$20.8M
-
Put/Call ratio
-
0.05
-
Number of buys
-
50
-
Number of sells
-
-38
-
Price
-
$1.56
Significant Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q4 2024
124 filings reported holding PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
of 62.9M outstanding shares and own 50.1% of the company stock.
Largest 10 shareholders include Pfizer Inc (7.03M shares), Laurion Capital Management LP (3.63M shares), BlackRock, Inc. (3.34M shares), MILLENNIUM MANAGEMENT LLC (2.98M shares), VANGUARD GROUP INC (2.44M shares), GEODE CAPITAL MANAGEMENT, LLC (1.08M shares), Palo Alto Investors LP (1.04M shares), STATE STREET CORP (944K shares), abrdn plc (913K shares), and Ikarian Capital, LLC (613K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.